This nationwide population-based nested case-control study has demonstrated an intensified effect of chronic viral hepatitis on premixed insulin analogues for HCC development among newly diagnosed type 2 diabetes patients ever prescribed any antidiabetic agents. This evidence concerns the gene INS and animal viral hepatitis.